LV
LAVA Therapeutics N.V.
LVTX · NASDAQ
$1.74 -3.87% (-$0.07)
Market Cap $45.8M
P/E Ratio -
Div. Yield -
ROE 108.07%
Piotroski F-Score Weak
2/9Valuation
68 /100
Cheap P/B 3.61x
P/FCF 3.20x
P/S 9.17x
Growth
100 /100
Growing Book val. growth 134.99%
Rev. growth N/A
FCF growth N/A
Profitability
30 /100
Weak Net margin 466.43%
Op. margin 440.34%
FCF margin 286.37%
Quality
1 /100
Poor ROE 108.07%
ROA 44.83%
Asset turnover 0.10x
Debt
57 /100
Moderate Current ratio 12.27x
Int. coverage -23.12x
Net debt/EBITDA 3.38x
Stability
28 /100
Unstable EPS volatility 92.03%
Profitable years 0
Beta 0.50x
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about LVTX
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Stephen Allen Hurly
Employees
34
Headquarters
Utrecht